Can your LX-2 assay distinguish between a compound that kills activated HSCs and one that genuinely reverses the fibrotic phenotype?

Absolutely. Our service incorporates multiplexed analysis, including a dedicated viability assay, alongside tracking specific deactivation markers and proliferation markers. This multiparametric approach ensures you confidently distinguish true antifibrotic action from non-specific cytotoxicity.

What is the main advantage of using your LX-2 model compared to primary human or rodent HSCs for high-throughput screening?

While primary cells offer undeniable biological relevance, LX-2 cells provide superior reproducibility, high availability, and a standardized human genetic background necessary for HTS and reliable IC50 determination.

How do you confirm the activation of the three different pathways in the LX-2 cells simultaneously?

TGF-β1 drives the classical fibrotic response, while the inclusion of inflammatory cytokines like TNF-α is necessary to fully trigger the retinoid dysregulation pathway. We rigorously confirm activation by validating the expected shifts in key markers before any compound screening begins.

LX-2 Cell-based Antagonist Assay Service

At Creative Biolabs, we have leveraged the immortal LX-2 cell line, a human hepatic stellate cell (HSC) line, to develop advanced antagonist assays aimed at evaluating potential antifibrotic compounds. LX-2 cells preserve the functional characteristics of in vivo HSCs and are used to screen inhibitors effectively through high-content analyses. These assays provide precise quantifications of the fibrogenic responses and antagonistic effects of test compounds, solidifying our position at the forefront of fibrosis research.

Introduction: LX-2 Cell-based Antagonist Assay Fundamentals

Liver fibrosis is fundamentally defined by the activation of quiescent HSCs into highly contractile, matrix-producing myofibroblasts. This transdifferentiation process leads to the pathogenic, excessive deposition of extracellular matrix (ECM), primarily collagen type I. Our service utilizes the immortalized human LX-2 cell line as the industry standard model for HSC activation due to its human origin, reliable proliferative capacity, and retention of critical cytokine receptors. The assay is strategically configured to interrogate multiple recently validated profibrotic pathways, including Wnt/PAI-1, RNF2/MAPK (ERK/p38), and cytokine-mediated retinoid dysregulation (LRAT/CRBP1), providing high-fidelity, human-relevant data for candidate validation.

Key Deliverables Through Mechanistic Targeting

Targeting the Wnt/β-catenin and PAI-1 Axis

HSC activation relies on Wnt/β-catenin signaling, driving proliferation and profibrotic mediator secretion like plasminogen activator inhibitor-1 (PAI-1). PAI-1 inhibits ECM degradation. Our assays quantify your compound's inhibition of β-catenin nuclear translocation and suppression of PAI-1 expression (mRNA/protein), linking efficacy to restored ECM turnover.

Analyzing the RNF2/MAPK Signaling Cascade

The E3 ubiquitin ligase RNF2 promotes fibrogenesis by activating the MAPK pathway. We measure phosphorylation inhibition of downstream kinases ERK1/2 and p38, providing mechanistic validation of your candidate as an upstream signal modulator.

Validating Cytokine-Mediated Retinoid Dysregulation

Activated HSCs lose vitamin A stores, driven by cytokines like TNF-α and IL-1β that suppress key enzymes LRAT and CRBP1. Our service assesses your compound's ability to preserve these markers, offering early validation of HSC deactivation potential.

Ready to accelerate your antifibrotic pipeline? Contact us today to discuss how our high-content LX-2 assay can validate your lead compounds and move your program closer to the clinic.

Workflow for LX-2 Antagonist Screening

Our assay is meticulously designed to provide robust and reproducible results, allowing for the reliable quantification of a test compound's ability to prevent or reverse the fibrogenic process.

Publication

This study investigates the anti-fibrotic mechanism of eupatilin, a natural flavonoid, in hepatic fibrosis. Using the human hepatic stellate cell line LX-2 and a CCl4-induced mouse model, the research demonstrates that eupatilin significantly alleviates liver fibrosis. It suppresses HSC activation, proliferation, and the epithelial-mesenchymal transition (EMT) process. The underlying mechanism involves the inhibition of the β-catenin pathway, reducing its nuclear translocation and subsequently downregulating its key downstream target, plasminogen activator inhibitor-1 (PAI-1). This work identifies eupatilin as a promising therapeutic agent and a natural PAI-1 inhibitor for treating hepatic fibrosis.

Why Choose Us

Creative Biolabs is your specialized partner in antifibrotic drug discovery, offering unparalleled depth in liver fibrosis modeling. Our advantage lies in combining the human-relevant LX-2 cell model with advanced, multi-mechanistic readout capabilities targeting underlying drivers of HSC activation. We offer Deep Mechanistic Validation targeting three critical pathways and customizable phenotype selection. Utilizing cutting-edge imaging platforms for detailed, multiparametric data, our integrated service offering bridges LX-2 assays with follow-up 3D spheroid models. We provide validated, actionable data that significantly accelerates your drug development decisions.

FAQs

Customer Review

Related Services

To ensure a seamless transition from lead identification to preclinical validation, Creative Biolabs offers several complementary services that can be integrated with your LX-2 antagonist assay:

Fibrosis Biomarker Panel Screening Service

Our service provides in-depth fibrosis biomarker analysis via high-throughput assays and cellular models, accelerating the discovery of novel targets and the evaluation of therapeutic candidates.

Learn More →

Drug Metabolic Stability Analysis Service

Creative Biolabs offers in vitro metabolic stability assays to predict drug behavior in vivo. This service identifies therapeutic drugs with optimal metabolic stability, ensuring favorable bioavailability and reduced toxicity risk.